grade
pharmaceutical primary standard
API family
pentoxifylline
manufacturer/tradename
USP
application(s)
pharmaceutical (small molecule)
format
neat
SMILES string
CN1C=NC2C1C(=O)N(CCCCC(C)=O)C(=O)N2C
InChI
1S/C13H20N4O3/c1-9(18)6-4-5-7-17-12(19)10-11(14-8-15(10)2)16(3)13(17)20/h8,10-11H,4-7H2,1-3H3
InChI key
MQGNNJQTNFHNHK-UHFFFAOYSA-N
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Pentoxifylline USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
- Pentoxifylline Compounded Oral Suspension
- Pentoxifylline Extended-Release Tablets
Biochem/physiol Actions
Phosphodiesterase inhibitor; inhibits synthesis of tumor necrosis factor α (TNF-α).
Analysis Note
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
Other Notes
Sales restrictions may apply.
Still not finding the right product?
Explore all of our products under 己酮可可碱
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral - Lact.
存储类别
11 - Combustible Solids
法规信息
涉药品监管产品
此项目有
R Parker et al.
Alimentary pharmacology & therapeutics, 37(9), 845-854 (2013-03-16)
Acute alcoholic hepatitis (AH) is a severe manifestation of alcoholic liver disease with a grave prognosis. Pentoxifylline, an oral antitumour necrosis factor agent, has been reported to reduce mortality and incidence of hepatorenal syndrome (HRS) in severe alcoholic hepatitis (SAH).
Simone Appenzeller et al.
Rheumatology international, 31(11), 1511-1513 (2009-12-17)
Behcet's disease is an inflammatory disorder of unknown cause, characterized by recurrent oral aphthous ulcers, genital ulcers, uveitis, and skin lesions. All these common manifestations are self-limiting except for the ocular attacks. The objective of the present study is to
Shirinsadat Badri et al.
Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques, 14(1), 128-137 (2011-04-20)
Chronic kidney disease (CKD) as a considerable health problem may have proteinuria as the main complication and strong risk factor to reach end-stage renal disease (ESRD). Decreasing proteinuria is the mainstay of therapy in order to delay the progression of
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| 1508901-200MG | 04061833860823 |